Recent advancements in non-viral gene editing technologies offer precise genome engineering at significantly reduced costs and biosafety risks compared to viruses. CRISPR is a programmable genome targeting system, which relies…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
Here, we demonstrate that dbDNATM can be optimised for the manufacture of high titre LVV.
Read More
The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated…
Read More
Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first…
Read More
A critical bottleneck for rapid onset of clinical trials as well as for resilient supply of commercial RNA products is the production of plasmid DNA, which is routinely used as…
Read More
Within advanced therapy manufacturing, more and more companies are turning to enzymatically produced DNA as an alternative to plasmid DNA.
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction…
Read More
ELENA STOYANOVA, PH.D. & TOM ADIE, PH.D. Touchlight is at the forefront of innovation in gene editing technology with our groundbreaking MegaBulb DNA (mbDNA). This novel, circular, single-stranded DNA template…
Read More
